Secukinumab

Secukinumab is a biologic medication primarily used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that specifically targets interleukin17A (IL-17A), a protein involved in inflammatory processes. By inhibiting IL-17A, Secukinumab helps reduce inflammation and the symptoms associated with these chronic conditions, improving the quality of life for many patients.

Uses of Secukinumab

Secukinumab is approved for several medical uses, including:

• Plaque Psoriasis: It is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis: Secukinumab is indicated for the treatment of active psoriatic arthritis in adults, either alone or in combination with other medications.
• Ankylosing Spondylitis: It is also approved for treating active ankylosing spondylitis in adults, a type of arthritis that primarily affects the spine.
• Non-radiographic Axial Spondyloarthritis: Secukinumab is indicated for patients with this condition who have evidence of inflammation.

How Does It Work?

Secukinumab works by blocking the action of interleukin17A, a cytokine that plays a crucial role in the inflammatory response. In simpler terms, think of IL-17A as a signal that tells the immune system to attack the body?s own tissues, leading to inflammation and symptoms like pain, redness, and swelling. By inhibiting this signal, Secukinumab helps to calm the immune response, reducing inflammation, and alleviating symptoms associated with autoimmune diseases.

Dosage and Administration

Secukinumab is administered via injection. The standard dosage for adults varies depending on the condition being treated:

• Plaque Psoriasis: The initial dose is typically 300 mg (administered as two 150 mg injections) at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 300 mg every four weeks.
• Psoriatic Arthritis: The initial dose is also 300 mg in weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 300 mg every four weeks. Alternatively, a 150 mg dose can be given every four weeks after the initial loading doses.
• Ankylosing Spondylitis: The initial dose is 150 mg (one injection) or 300 mg (two injections) at weeks 0, 1, 2, 3, and 4, followed by 150 mg or 300 mg every 4 weeks.

For pediatric patients (plaque psoriasis ages 6, psoriatic arthritis ages 2, enthesitis-related arthritis ages 4), the dosage is weight-based and varies; no broad approval for ankylosing spondylitis or nr-axSpA. Consult labeling and healthcare providers.

Side Effects of Secukinumab

Like all medications, Secukinumab can cause side effects.

Common side effects include:

• Injection site reactions (redness, swelling, pain)
• Upper respiratory infections (cold like symptoms)
• Headache
• Nausea
• Gastrointestinal issues (diarrhea, abdominal pain)

Serious side effects may include:

• Increased risk of infections (due to immune suppression)
• Allergic reactions (rash, itching, swelling)
• Changes in liver function tests
• Inflammatory bowel disease (new onset or exacerbation)

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Secukinumab may interact with other medications, which can affect its efficacy or increase the risk of side effects. Major drug interactions include:

• Live Vaccines: Patients should avoid live vaccines while on Secukinumab due to the risk of infections.
• Immunosuppressants: Caution is advised when used with other immunosuppressive drugs, as this may increase the risk of infections.
• Other Biologics: Combining Secukinumab with other biologic therapies is generally not recommended.

Always inform your healthcare provider about all the medications and supplements you are taking.

Benefits of Secukinumab

Secukinumab offers several clinical and practical advantages:

• Targeted Therapy: It specifically targets IL-17A, which may lead to more effective treatment with fewer side effects compared to traditional systemic therapies.
• Rapid Onset of Action: Many patients experience relief from symptoms within weeks of starting treatment.
• Improved Quality of Life: By effectively managing symptoms, Secukinumab can significantly enhance the quality of life for individuals with chronic autoimmune conditions.
• Convenient Administration: The injection can be done at home after proper training, making it easier for patients to manage their treatment.

Contraindications of Secukinumab

Certain individuals should avoid using Secukinumab, including:

• Pregnant or Nursing Women: Category not assigned; use only if potential benefit justifies risk (limited data). Registry recommended.
• Individuals with Active Infections: Patients with ongoing infections should not start treatment until the infection is resolved.
• History of Severe Allergic Reactions: Those with a known hypersensitivity to Secukinumab or any of its components should not use this medication.

Precautions and Warnings

Before starting Secukinumab, patients should undergo specific evaluations:

• Infection Screening: Patients should be screened for tuberculosis (TB) and other infections before initiating therapy.
• Liver Function Tests: Not routinely required unless pre-existing liver disease; monitor if symptoms arise.
• Vaccination Status: Ensure that vaccinations are up to date before starting treatment, particularly for pneumococcal and influenza vaccines.

FAQs

• What is Secukinumab used for? Secukinumab is used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
• How is Secukinumab administered? It is administered via injection, typically under the skin, with specific dosing schedules depending on the condition being treated.
• What are the common side effects? Common side effects include injection site reactions, upper respiratory infections, headache, and nausea.
• Can I take Secukinumab if I am pregnant? It is generally advised to avoid Secukinumab during pregnancy due to potential risks to the fetus.
• How quickly can I expect results? Many patients notice improvements within a few weeks of starting treatment, but individual responses may vary.
• Are there any serious side effects? Yes, serious side effects can include increased risk of infections and allergic reactions. Report any unusual symptoms to your doctor.
• Can I receive vaccinations while on Secukinumab? Live vaccines should be avoided, but non-live vaccines may be administered. Consult your healthcare provider for guidance.
• What should I do if I miss a dose? If you miss a dose, take it as soon as you remember. If it's close to the time of your next dose, skip the missed dose and continue with your regular schedule.
• Is Secukinumab safe to use with other medications? Inform your doctor about all the medications you are taking, as some may interact with Secukinumab.
• How long will I need to take Secukinumab? The duration of treatment varies depending on the individual's condition. Your doctor will determine the best plan for you.

Brand Names

Secukinumab is available as Cosentyx (primary brand); generic not yet available as of 2025.

Conclusion

Secukinumab represents a significant advancement in the treatment of autoimmune diseases, offering targeted therapy that can lead to improved outcomes for patients. With its specific mechanism of action, it provides relief from symptoms of conditions like psoriasis and psoriatic arthritis, enhancing the quality of life for many. However, it is essential to use this medication under the guidance of a healthcare provider, considering potential side effects and contraindications.